SCHEMBL5125735

SCHEMBL5125735

[C-]#[N+]/C(C(=O)OCC)=C(\Br)c1ccccc1Cl

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 1/20 0.42
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
ALDH1A1 P00352 6/20 0.37
HSD17B10 Q99714 1/20 0.37
HPGD P15428 2/20 0.37
GPR35 Q9HC97 1/20 0.37
USP2 O75604 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM5 P08912 1/20 0.37
CHRM3 P20309 1/20 0.37
GLA P06280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5125736 1.00 CASP1 (0.42) CASP1LMNATSHRKMT2AMEN1
SCHEMBL5125748 0.85 CASP1 (0.43) CASP1LMNATSHRKMT2AMEN1
SCHEMBL5125753 0.85 CASP1 (0.43) CASP1LMNATSHRKMT2AMEN1
SCHEMBL5120430 0.85 TSHR (0.42) LMNATSHRKMT2AMEN1ALDH1A1
SCHEMBL3492575 0.80 ALDH1A1 (0.49) LMNATSHRKMT2AMEN1ALDH1A1
SCHEMBL6220983 0.80 TSHR (0.46) CASP1LMNATSHRKMT2AMEN1
SCHEMBL6220985 0.80 TSHR (0.46) CASP1LMNATSHRKMT2AMEN1
SCHEMBL3492571 0.80 ALDH1A1 (0.49) LMNATSHRKMT2AMEN1ALDH1A1
SCHEMBL5124143 0.76 F2R (0.41) LMNATSHRKMT2AMEN1ALDH1A1
SCHEMBL5124144 0.76 F2R (0.41) LMNATSHRKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161573-A1 PROCESS FOR THE PREPARATION OF IMIQUIMOD AND INTERMEDIATES THEREOF DIPHARMA S.P.A. (IT) 2008-07-03 US disclosed
US-7301027-B2 Process for the preparation of Imiquimod and intermediates thereof DIPHARMA S.P.A. (IT) 2007-11-27 US disclosed
US-20050165236-A1 Process for the preparation of Imiquimod and intermediates thereof DIPHARMA S.P.A. (IT) 2005-07-28 US disclosed
EP-1529781-A1 A process for the preparation of Imiquimod and intermediates thereof Dipharma S.p.A. (IT) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161573-A1 PROCESS FOR THE PREPARATION OF IMIQUIMOD AND INTERMEDIATES THEREOF MYD88, TLR7, MAVS CASP1 489/4885LMNA 1612/4885TSHR 4552/4885
US-20050165236-A1 Process for the preparation of Imiquimod and intermediates thereof MYD88, TLR7, MAVS CASP1 456/4885LMNA 1417/4885TSHR 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.